Johnson & Johnson (JNJ) down -1.09 per cent in the past week, is under coverage of 23 analysts who collectively recommend a hold rating on stock. 11 of the analysts have a buy or better rating; the 11 sells versus 1 holds. The 18 equity analysts who rate the stock have an average target price at $115.78, with individual targets ranging between $99 and $126. The shares closed last trade at $112.08, implying that analysts see shares rising about 3.3 per cent in 12 months’ time.
Insider Activity: Insiders look pessimistic about the prospects of the company that they seem to offload shares while they are 9.9 up so far this year. A VP, Global Human Resources at Johnson & Johnson (JNJ) sold shares in the company in a transaction completed on Wednesday February 03, 2016. Fasolo Peter offloaded 144,568 shares in the company at an average price of $104.12 and ended up generating $15,052,420 in proceeds. Fasolo Peter retains 37,735 shares in the company after this transaction. A VP, Global Human Resources in the company, Fasolo Peter, on Tuesday February 02, 2016 collected $709,588 from the sale of 6,817 shares at $104.12 each. Insiders are expected to know better about the health and prospects of their company, which is why insiders’ move deserves attention.
Earnings to Watch: Investors considering JNJ stock at the going market price of $112.08/share should know the stock will next release quarterly results for the June 2016 quarter. For the reporting quarter, analysts expect the company to deliver $1.68 in earnings per share (EPS). That would represent a -1.75% year-over-year decrease Revenue for the same period is expected to arrive at $18.01B.
Earnings Roundup: In the last fiscal quarter alone, Johnson & Johnson generated around $17.48B in revenue and net income of $1.68/share. That compares with the consensus estimate $17.48B and $1.65/share, respectively. For the three months through December 2015, revenue for the company hit $17.81B, with earnings at $1.44/share.
Analyst Coverage: Goldman has been a brokerage house following shares of Johnson & Johnson (JNJ), so its rating change is noteworthy. The stock was upgraded to Neutral from Sell, wrote analysts at Goldman, in a note issued to clients on Monday March 14, 2016. There was another key note issued by Barclays on Friday January 10, 2014. The firm lowered its rating on JNJ from Overweight to Equal Weight.
Price Momentum: Despite the -0.36% decrease in value, the stock’s new closing price represents a -1.85% fall in value from company’s one year high of $114.19. The stock is currently holding above its 50 day moving average of $109.69 and above its 200 day moving average of $103.75. Over the last three months and over the last six months, the shares of Johnson & Johnson (JNJ), have changed 8.09% and 13.18, respectively.